Merck Calls Off Trial of Verubecestat as Treatment for Mild-to-Moderate Alzheimer’s

Merck Calls Off Trial of Verubecestat as Treatment for Mild-to-Moderate Alzheimer’s
Merck is calling off its Phase 2 and 3 EPOCH trial of verubecestat as a treatment for mild-to-moderate Alzheimer’s disease because preliminary results indicate it is not effective. The decision was made after an external review board known as the Data Monitoring Committee (eDMC) reported there was “virtually no chance of finding a positive clinical effect” from the

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *